Inhibitors of PIM‐2 have been shown to impact MM cell survival through the DNA damage pathway.[30, 34] Further, the PIM inhibitor AZD1208, in combination with Akt inhibitors, exhibits synergistic antitumor effects in gastric cancer cell lines, potentially mediated via modulation of DNA damage repair pathways.[35] These observations suggest that combining inhibitors of DNA damage repair enzymes may enhance the effectiveness of antimyeloma therapies. The gene discussed is PIM1; the disease is Miyoshi myopathy.